Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Juan M. Ortega-Legaspi"'
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 11, Iss , Pp 100255- (2023)
Interferons are widely expressed cytokines that possess potent anti-viral and anti-tumor activity. As therapeutic agents, interferons have proven useful in treating assorted cancers, chronic infections, and autoimmune disease. However, interferon the
Externí odkaz:
https://doaj.org/article/7e53a195987345338f4fbd31338235b2
Autor:
Lauren Andrade, Juan M. Ortega-Legaspi, Katherine Awh, Stephanie Fuller, Bhavesh Patel, Lynda Tobin, Joyce Wald, Yuli Y. Kim
Publikováno v:
International Journal of Cardiology Congenital Heart Disease, Vol 8, Iss , Pp 100387- (2022)
Objectives: To explore diuretic use in Fontan patients and its association with clinical features and adverse outcomes. Background: In Fontan circulatory failure, ventricular dysfunction, chronically elevated systemic venous pressures, lymphatic abno
Externí odkaz:
https://doaj.org/article/7505330031884c0981f7e74794f934cc
Autor:
Ayan Ali, Juan M. Ortega-Legaspi
Publikováno v:
Annals of palliative medicine. 11(10)
Autor:
Francisco Pellicer, Juan M Ortega-Legaspi, Rodrigo Martín, Sergio Solís-Nájera, Lucía Magis-Weinberg, Martha León-Olea, Ariel Graff-Guerrero, Camilo de la Fuente-Sandoval, Alfredo O Rodriguez
Publikováno v:
Journal of pain research. 15
Francisco Pellicer,1 Juan M Ortega-Legaspi,2 Rodrigo Martín,3 Sergio Solís-Nájera,4 Lucía Magis-Weinberg,5 Martha León-Olea,6 Ariel Graff-Guerrero,7,8 Camilo de la Fuente-Sandoval,9 Alfredo O Rodriguez3 1Laboratorio de Neurofisiología Integrati
Publikováno v:
Current opinion in organ transplantation. 25(5)
Purpose of review Understanding the mechanisms involved in immune protection provided by a hepatic allograft is imperative as further therapies for highly sensitized patients could be developed and thus expanding the donor pool and improving outcomes
Autor:
Lauren B. Cooper, V. Maharaj, Adam D. DeVore, Palak Shah, Eileen K Maziarz, Juan M Ortega-Legaspi, Maureen Flattery, Keyur B. Shah, Robert T. Cole, Tamas Alexy, Christopher T. Martin, E. Udeshi, Maria Molina, Alanna A. Morris
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S116-S117
Purpose Heart Transplant recipients previously exposed to CMV infection are considered intermediate risk for post-transplant CMV complications. Many centers therefore utilize "universal" prophylaxis for 3-6 months to mitigate this risk. However, it r
Publikováno v:
Journal of Cardiology Cases. 15:28-31
We describe the case of a 49-year-old woman with metastatic renal carcinoma receiving treatment with high-dose interleukin-2 (IL-2) who developed acutely progressive dyspnea on exertion and an elevated troponin level. Cardiac magnetic resonance imagi
Publikováno v:
Clinical Infectious Diseases
Publikováno v:
Clinical Infectious Diseases
Autor:
Adam D. DeVore, Palak Shah, Maureen Flattery, K. Nair, Alanna A. Morris, Robert T. Cole, Tamas Alexy, Juan M Ortega-Legaspi
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S117
Purpose Heart transplant recipients with prior exposure to CMV (R+) are considered intermediate risk for CMV-related complications, and current guidelines allow for either universal prophylaxis or a pre-emptive approach to prophylaxis. Some centers p